arrow
D

Derek R. Johnson

mayo clinic rochester
H指数:31
被引数:4,077

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A model of brain function to predict tau across Alzheimer’s disease and related disorders

阿尔茨海默病及相关障碍中预测tau蛋白的脑功能模型

2026-10-020
OAAI
WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids

WSB1介导的PSMA泛素化促进恩扎卢替尼诱导的病人源性前列腺癌细胞球类神经内分泌样转化

2026-08-020
OA
Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience

ivosidenib在主要复发性IDH1突变型胶质瘤中的应用:一项单机构经验

2026-05-010
PRE
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial

安全性、耐受性和免疫原性:一项在美国50岁及以上健康成人中进行的31价肺炎球菌结合疫苗(VAX-31)的Ⅰ/Ⅱ期、双盲、活性对照、平行组、剂量探索随机临床试验

2026-03-180
PRE
Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma

177Lu-DOTATATE肽受体放射性核素治疗在转移性嗜铬细胞瘤和副神经节瘤患者中的疗效

2026-01-010
PRE
American Society of Neuroradiology Consensus Statement: Integrating Neuro-PET Interpretation into Neuroradiology Training and Practice

美国神经放射学会共识声明:将神经PET解读整合到神经放射学培训和实践中

2026-01-010
PRE
Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based on 18F-DOPA PET Images

基于18F-DOPA PET图像的放射组学分析预测胶质母细胞瘤患者的剩余生存期

2025-11-030
OAAI
MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523)

MOMENTUM-1:一项多中心、随机、开放标签的II期研究,评估[177Lu]Lu-DOTA-TATE在进展性1-3级脑膜瘤成人患者中的疗效(RTOG 3523)。

2025-11-010
OAAI
Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case–control study

阿尔茨海默病中,接受阿杜单抗治疗与未治疗患者的神经病理学改变及淀粉样蛋白相关影像学异常:一项回顾性病例对照研究

2025-10-150
PRE
Calibration of multisite raters for prospective visual reads of amyloid PET scans

多站点评分者对淀粉样蛋白PET扫描前瞻性视觉读片的校准

2025-09-300
OAAI
Staging Alzheimer’s disease through amyloid and tau PET

通过淀粉样蛋白和tau PET对阿尔茨海默病进行分期

Brain
IF11.7
2025-09-190
PRE
Analysis of imaging signatures in 18F-DOPA PET of glioblastoma treated with dose-escalated radiotherapy

18F-DOPA PET中经剂量递增放射治疗的胶质母细胞瘤成像特征分析

2025-08-130
OA
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas

更新RANO工作组及EANO关于PET成像在胶质瘤临床应用的建议

2025-07-280
OAAI
[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases

[177Lu] Lu-PSMA-617治疗伴有脑部和脑桥部转移的转移性去势抵抗性前列腺癌(mCRPC)

2025-07-210
PRE
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma

关于North Central Cancer Treatment Group N0877(alliance)的最终报告:一项关于胶质母细胞瘤的II期随机、安慰剂对照试验,评估含或不含达沙替尼的放化疗。

2025-07-011
OAAI
RANO criteria for response assessment of brain metastases based on amino acid PET imaging

基于氨基酸PET成像的脑转移瘤疗效评价的RANO标准

2025-05-081
PRE
Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis

表征成人中线胶质瘤的分子和空间异质性: 单一机构分析

2025-03-010
PRE